Literature DB >> 19535993

Leucine-rich repeat kinase 2 expression leads to aggresome formation that is not associated with alpha-synuclein inclusions.

Elisa A Waxman1, Jason P Covy, Irene Bukh, Xiaojie Li, Ted M Dawson, Benoit I Giasson.   

Abstract

Mutations in leucine-rich repeat kinase-2 (LRRK2) are the most common known cause of Parkinson disease, but how this protein results in the pathobiology of Parkinson disease is unknown. Moreover, there is variability in pathology among cases, and alpha-synuclein (alpha-syn) neuronal inclusions are often present, but whether LRRK2 is present in these pathological inclusions is controversial. This study characterizes novel LRRK2 antibodies, some of which preferentially recognize an aggregated form of LRRK2, as observed in cell culture models. Large perinuclear aggregates containing LRRK2 were promoted by proteasome inhibition and prevented by microtubule polymerization inhibition. Furthermore, they were vimentin- and gamma-tubulin- but not lamp1-immunoreactive, suggesting that these structures fit the definition of aggresomes. Inhibition of heat shock protein 90 led to the degradation of only the soluble/cytosolic pool of LRRK2, suggesting that the aggresomes formed independent of the stability provided by the heat shock protein 90. Although these novel anti-LRRK2 antibodies identified aggregates in model cell systems, they did not immunostain pathological inclusions in human brains. Furthermore, coexpression of LRRK2 and alpha-syn did not recruit alpha-syn into aggresomes in cultured cells, even in the presence of proteasome inhibition. Thus, although LRRK2 is a model system for aggresome formation, LRRK2 is not present in alpha-syn pathological inclusions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19535993      PMCID: PMC2722758          DOI: 10.1097/NEN.0b013e3181aaf4fd

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  44 in total

1.  Characterization of cytoplasmic alpha-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells.

Authors:  He-Jin Lee; Seung-Jae Lee
Journal:  J Biol Chem       Date:  2002-09-25       Impact factor: 5.157

2.  LRRK2 protein is a component of Lewy bodies.

Authors:  Xiongwei Zhu; Sandra L Siedlak; Mark A Smith; George Perry; Shu G Chen
Journal:  Ann Neurol       Date:  2006-11       Impact factor: 10.422

3.  Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes.

Authors:  Kazuko Hasegawa; A Jon Stoessl; Teruo Yokoyama; Hisayuki Kowa; Zbigniew K Wszolek; Saburo Yagishita
Journal:  Parkinsonism Relat Disord       Date:  2008-09-18       Impact factor: 4.891

4.  N-methyl-D-aspartate receptors expressed in a nonneuronal cell line mediate subunit-specific increases in free intracellular calcium.

Authors:  E R Grant; B J Bacskai; D E Pleasure; D B Pritchett; M J Gallagher; S J Kendrick; L J Kricka; D R Lynch
Journal:  J Biol Chem       Date:  1997-01-03       Impact factor: 5.157

5.  Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates.

Authors:  Joseph R Mazzulli; Amanda J Mishizen; Benoit I Giasson; David R Lynch; Steven A Thomas; Akira Nakashima; Toshiharu Nagatsu; Akira Ota; Harry Ischiropoulos
Journal:  J Neurosci       Date:  2006-09-27       Impact factor: 6.167

Review 6.  LRRK2 and neurodegeneration.

Authors:  Gabriel Santpere; Isidre Ferrer
Journal:  Acta Neuropathol       Date:  2009-01-14       Impact factor: 17.088

7.  The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity.

Authors:  Barrington Burnett; Fusheng Li; Randall N Pittman
Journal:  Hum Mol Genet       Date:  2003-10-14       Impact factor: 6.150

8.  Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases.

Authors:  John E Duda; Benoit I Giasson; Meghann E Mabon; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2002-08       Impact factor: 10.422

9.  LRRK2 in Parkinson's disease and dementia with Lewy bodies.

Authors:  Xiongwei Zhu; Asim Babar; Sandra L Siedlak; Qiwei Yang; Genta Ito; Takeshi Iwatsubo; Mark A Smith; George Perry; Shu G Chen
Journal:  Mol Neurodegener       Date:  2006-11-30       Impact factor: 14.195

10.  Aggresomes: a cellular response to misfolded proteins.

Authors:  J A Johnston; C L Ward; R R Kopito
Journal:  J Cell Biol       Date:  1998-12-28       Impact factor: 10.539

View more
  19 in total

1.  The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation.

Authors:  Iakov N Rudenko; Alice Kaganovich; David N Hauser; Aleksandra Beylina; Ruth Chia; Jinhui Ding; Dragan Maric; Howard Jaffe; Mark R Cookson
Journal:  Biochem J       Date:  2012-08-15       Impact factor: 3.857

2.  Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities.

Authors:  Philip J Webber; Archer D Smith; Saurabh Sen; Matthew B Renfrow; James A Mobley; Andrew B West
Journal:  J Mol Biol       Date:  2011-07-22       Impact factor: 5.469

3.  Lrrk2 localization in the primate basal ganglia and thalamus: a light and electron microscopic analysis in monkeys.

Authors:  H Lee; H L Melrose; M Yue; Jean-Francois Pare; M J Farrer; Y Smith
Journal:  Exp Neurol       Date:  2010-05-17       Impact factor: 5.330

4.  Induction of intracellular tau aggregation is promoted by α-synuclein seeds and provides novel insights into the hyperphosphorylation of tau.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  J Neurosci       Date:  2011-05-25       Impact factor: 6.167

5.  Characterization of kinases involved in the phosphorylation of aggregated α-synuclein.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  J Neurosci Res       Date:  2010-12-08       Impact factor: 4.164

6.  A novel, high-efficiency cellular model of fibrillar alpha-synuclein inclusions and the examination of mutations that inhibit amyloid formation.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  J Neurochem       Date:  2010-02-02       Impact factor: 5.372

7.  Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).

Authors:  Eva Andres-Mateos; Rebeca Mejias; Masayuki Sasaki; Xiaojie Li; Brian M Lin; Saskia Biskup; Li Zhang; Rebecca Banerjee; Bobby Thomas; Lichuan Yang; Guosheng Liu; M Flint Beal; David L Huso; Ted M Dawson; Valina L Dawson
Journal:  J Neurosci       Date:  2009-12-16       Impact factor: 6.167

Review 8.  Cellular effects of LRRK2 mutations.

Authors:  Mark R Cookson
Journal:  Biochem Soc Trans       Date:  2012-10       Impact factor: 5.407

9.  Impaired tau-microtubule interactions are prevalent among pathogenic tau variants arising from missense mutations.

Authors:  Yuxing Xia; Zachary A Sorrentino; Justin D Kim; Kevin H Strang; Cara J Riffe; Benoit I Giasson
Journal:  J Biol Chem       Date:  2019-10-24       Impact factor: 5.157

10.  Leucine-rich repeat kinase 2 (LRRK2)-deficient rats exhibit renal tubule injury and perturbations in metabolic and immunological homeostasis.

Authors:  Daniel Ness; Zhao Ren; Shyra Gardai; Douglas Sharpnack; Victor J Johnson; Richard J Brennan; Elizabeth F Brigham; Andrew J Olaharski
Journal:  PLoS One       Date:  2013-06-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.